The global Opioid Induced Constipation (OIC) Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
The global Opioid Induced Constipation (OIC) Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Opioid Induced Constipation (OIC) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Geographical Analysis:
Based on region, the global Opioid Induced Constipation (OIC) Drug market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Opioid Induced Constipation (OIC) Drug market are
Ironwood Pharmaceuticals
Daiichi Sankyo Co
Pfizer
Progenics Pharmaceuticals
Shionogi &
Allergan
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma
Mundipharma International Limited
Ono Pharmaceutical
Takeda Pharmaceutical Company Limited
Theravance Biopharma
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies